EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A comprehensive analysis of adverse drug reactions in 2020–2023: case studies

Jinghui Zhai, Hongzhe Yan, Jinping Zhang, Huiyu Yan, Jie Ma, Sixi Zhang

Frontiers in Pharmacology · 02.10.2025 · 16

DOI: 10.3389/fphar.2025.1628347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.10.2025. Verfasst von Jinghui Zhai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adverse drug reactions (ADRs) have posed significant threats to patient safety and could potentially result in adverse clinical outcomes.

Methods

In this study, we analyzed ADRs data reported by a large hospital spanning from 2020 to 2023, with a particular focus on identifying demographic and clinical factors associated with severe ADRs. The dataset encompassed 5,644 cases, incorporating variables such as patient age, gender, smoking and drinking history, allergies, medication type, and administration route.

Results

Among these, 408 cases of severe ADRs underwent detailed examination. Additionally, the study delved into the correlation between adverse drug reactions symptoms (ADRS) and various drug types. According to research statistics, individuals in the middle-aged group (46–65 years) exhibited the highest proportion of severe ADRs at 36.77%. Females were significantly more affected than males, accounting for 66.67% of severe ADRs. Anti-tumor drugs emerged as the primary cause of severe ADRs, responsible for 52.70% of such incidents. Compared with other administration methods, intravenous injection was more prone to causing severe ADRs, with a likelihood of 53.92%. Furthermore, the blood system was identified as the ADRS where severe ADRs occurred at a significantly higher rate than other parts of the body, at 53.19%. Correlation analysis reveals a strong association between medication type and factors such as patient age, administration route, and ADRS. Notably, ADRS was also strongly linked to drug type, gender, and age.

Conclusion

These findings collectively highlight the critical need for personalized treatment plans and targeted monitoring. Particular attention should be directed towards high-risk groups, such as middle-aged females and patients undergoing anti-tumor therapies. By doing so, it is possible to enhance drug safety and minimize the occurrence of severe ADRs.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactionsanti-tumor drugclinical factorspersonalized treatmentsevere adverse drug reactions

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, The First Hospital of Jilin University, Changchun, Jilin, China.
  • School of Pharmaceutical Science, Jilin University, Changchun, Jilin, China.
  • Division of Clinical Research, the First Hospital of Jilin University, Changchun, Jilin, China.

Zitieren

APA

Zhai, J., Yan, H., Zhang, J., Yan, H., Ma, J., & Zhang, S. (2025). A comprehensive analysis of adverse drug reactions in 2020–2023: case studies. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1628347

Vancouver

Zhai J, Yan H, Zhang J, Yan H, Ma J, Zhang S. A comprehensive analysis of adverse drug reactions in 2020–2023: case studies. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1628347

BibTeX
@article{Zhai2025,
  author = {Zhai, Jinghui and Yan, Hongzhe and Zhang, Jinping and Yan, Huiyu and Ma, Jie and Zhang, Sixi},
  title = {A comprehensive analysis of adverse drug reactions in 2020–2023: case studies},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1628347}
}
Kostenlos starten →